A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ovarian cancer drug Zejula, which competes with AZ’s top-selling PARP inhibito
AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
